共 128 条
[1]
Katznelson L(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951
[2]
Laws ER(2013)Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists Clin Endocrinol (Oxf) 79 689-699
[3]
Melmed S(2014)Pasireotide versus octreotide in acromegaly: a head-to-head superiority study J Clin Endocrinol Metab 99 791-799
[4]
Howlett TA(2012)Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly Pituitary 15 398-404
[5]
Willis D(2006)First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial Clin Endocrinol (Oxf) 64 342-351
[6]
Walker G(2005)Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study J Endocrinol Invest 28 978-983
[7]
Colao A(2006)Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage J Clin Endocrinol Metab 91 1397-1403
[8]
Bronstein MD(2004)Efficacy of Sandostatin Clin Endocrinol (Oxf) 60 375-381
[9]
Freda P(2003) LAR J Clin Endocrinol Metab 88 3090-3098
[10]
Tutuncu Y(2001) (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy J Clin Endocrinol Metab 86 2779-2786